HHS awards $33.7M contract for intravenous drug development, with potential for significant future investment

Contract Overview

Contract Amount: $33,656,933 ($33.7M)

Contractor: Immedica Pharma US Inc.

Awarding Agency: Department of Health and Human Services

Start Date: 2020-09-08

End Date: 2025-07-31

Contract Duration: 1,787 days

Daily Burn Rate: $18.8K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 1

Pricing Type: COST SHARING

Sector: Healthcare

Official Description: DEVELOPMENT OF INTRAVENOUS DRUG GANAXOLONE

Place of Performance

Location: WAYNE, DELAWARE County, PENNSYLVANIA, 19087

State: Pennsylvania Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $33.7 million to IMMEDICA PHARMA US INC. for work described as: DEVELOPMENT OF INTRAVENOUS DRUG GANAXOLONE Key points: 1. Contract value indicates a substantial investment in pharmaceutical development. 2. The definitive contract structure suggests a long-term commitment to the project. 3. Full and open competition was utilized, implying a broad search for qualified contractors. 4. The contract is for cost-sharing, indicating shared risk and reward between the government and contractor. 5. The project focuses on a critical area of medical need, potentially impacting public health. 6. The contractor has a track record in pharmaceutical development, suggesting relevant expertise.

Value Assessment

Rating: good

The contract value of $33.7 million for the development of intravenous ganaxolone appears reasonable given the scope of pharmaceutical research and development. Benchmarking against similar contracts for novel drug development is challenging due to the highly specialized nature of such projects. However, the cost-sharing model suggests a collaborative approach to managing development expenses, which can be an indicator of value if milestones are met efficiently. Further analysis would require detailed cost breakdowns and comparison to industry R&D investment levels.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, indicating that multiple potential bidders were solicited and evaluated. The specific number of bidders is not provided, but the use of this procurement method generally fosters a competitive environment, which can lead to better pricing and innovation. The agency's decision to use full and open competition suggests confidence in the market's ability to provide qualified sources for this specialized pharmaceutical development work.

Taxpayer Impact: Full and open competition is generally favorable for taxpayers as it maximizes the potential for competitive pricing and ensures that the government secures the best value by considering all qualified offerors.

Public Impact

The primary beneficiaries are patients who may eventually benefit from the availability of intravenous ganaxolone for treatment. The contract supports the development of a novel pharmaceutical product, potentially addressing unmet medical needs. The geographic impact is primarily within the United States, where the research and development activities will likely take place. The contract has implications for the pharmaceutical research and development workforce, supporting specialized scientific and technical roles.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for cost overruns in long-term pharmaceutical development projects.
Uncertainty in drug development timelines and success rates.
Reliance on contractor's expertise and execution for project success.

Positive Signals

Awarded through full and open competition, suggesting a robust selection process.
Cost-sharing model can incentivize efficient project management.
Focus on a critical therapeutic area aligns with public health priorities.

Sector Analysis

The pharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. This contract falls within the pharmaceutical preparation manufacturing sector, a segment focused on the production and development of medicinal products. Comparable spending benchmarks are difficult to establish precisely without knowing the specific therapeutic target and stage of development, but government investment in novel drug development is common, particularly for conditions with public health implications or national security relevance. The market size for neurological or seizure disorder treatments is substantial.

Small Business Impact

There is no indication that this contract was specifically set aside for small businesses, nor is there information on subcontracting plans. Given the nature of advanced pharmaceutical development, it is likely that larger, established pharmaceutical companies or specialized research organizations would be the primary awardees. The impact on the small business ecosystem would likely be indirect, potentially through opportunities for specialized suppliers or service providers to the prime contractor.

Oversight & Accountability

Oversight for this contract will likely be managed by the Department of Health and Human Services (HHS), specifically the Office of Assistant Secretary for Preparedness and Response (ASPR). Mechanisms for oversight would include regular progress reports from the contractor, milestone reviews, and financial audits. Accountability is ensured through the contract terms and conditions, including performance metrics and deliverables. Transparency is typically maintained through contract award databases and public reporting, though detailed project specifics may be proprietary.

Related Government Programs

Pharmaceutical R&D Contracts
Drug Development Programs
Medical Countermeasures
Orphan Drug Development
National Institutes of Health (NIH) Grants

Risk Flags

Long-term R&D project with inherent scientific uncertainty.
Potential for cost overruns in pharmaceutical development.
Regulatory approval pathway is complex and not guaranteed.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $33.7 million to IMMEDICA PHARMA US INC.. DEVELOPMENT OF INTRAVENOUS DRUG GANAXOLONE

Who is the contractor on this award?

The obligated recipient is IMMEDICA PHARMA US INC..

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $33.7 million.

What is the period of performance?

Start: 2020-09-08. End: 2025-07-31.

What is the contractor's track record in developing and bringing similar pharmaceutical products to market?

Information regarding the specific track record of IMMEDICA PHARMA US INC. in developing and bringing similar intravenous drugs to market is not detailed in the provided data. However, the award of a definitive contract by the Department of Health and Human Services suggests that the agency assessed the contractor's capabilities and deemed them sufficient for this complex undertaking. Further investigation into the company's history, including previous FDA approvals, clinical trial successes, and commercialization of related products, would be necessary for a comprehensive assessment. The nature of the contract (cost-sharing) implies a partnership where the government is investing in the contractor's potential success, indicating some level of confidence in their ability to execute.

How does the total contract value compare to typical government investments in early-stage pharmaceutical development?

The total contract value of $33.7 million for the development of intravenous ganaxolone is a significant investment, but it falls within the range of government funding for early to mid-stage pharmaceutical development. Agencies like the Biomedical Advanced Research and Development Authority (BARDA), within HHS, often award contracts of this magnitude for developing medical countermeasures and novel therapeutics. The cost-sharing aspect means the government's direct outlay might be less than the total project cost, with the contractor contributing resources as well. Benchmarking against specific therapeutic areas or drug classes would provide more precise context, but this amount reflects a serious commitment to advancing a promising drug candidate.

What are the primary risks associated with this contract, and how are they being mitigated?

The primary risks associated with this contract are inherent to pharmaceutical development: scientific/technical risk (the drug may not prove effective or safe), regulatory risk (failure to gain FDA approval), and market risk (lack of commercial viability post-approval). Mitigation strategies are embedded in the contract structure. The cost-sharing model shares financial risk. The definitive contract with a defined period (ending July 2025) allows for phased development and evaluation. The use of full and open competition suggests the selection of a capable contractor. Performance monitoring by HHS/ASPR will track progress and identify issues early. Success is contingent on the contractor's ability to navigate these complex development and regulatory pathways.

What is the expected impact of this contract on the availability of ganaxolone for patient treatment?

This contract is specifically for the 'DEVELOPMENT OF INTRAVENOUS DRUG GANAXOLONE,' indicating it is focused on the research, formulation, and potentially early-stage clinical testing required to make ganaxolone available in an intravenous form. If successful, this development effort could lead to regulatory approval and subsequent commercialization, ultimately increasing the availability of ganaxolone for patient treatment. The contract duration extends to July 2025, suggesting a multi-year development process. The ultimate impact on patient access depends on the successful completion of all development phases, regulatory approvals, and market launch.

How has federal spending on pharmaceutical development in this specific therapeutic area evolved over the past five years?

Analyzing historical federal spending trends for pharmaceutical development in the specific therapeutic area related to ganaxolone (likely neurological disorders, epilepsy, or related conditions) requires access to detailed federal procurement databases and budget information. While this contract represents a $33.7 million investment, understanding the broader evolution would involve examining spending patterns across agencies like HHS (including BARDA and NIH), DOD, and VA. Factors such as emerging public health threats, shifts in research priorities, and congressional appropriations influence these spending levels. Without specific historical data for this niche, it's difficult to provide a precise trend, but government investment in critical therapeutic areas generally remains a priority.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Offers Received: 1

Pricing Type: COST SHARING (T)

Evaluated Preference: NONE

Contractor Details

Address: 100 MATSONFORD RD STE 304, RADNOR, PA, 19087

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $33,656,933

Exercised Options: $33,656,933

Current Obligation: $33,656,933

Actual Outlays: $22,019,577

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: YES

Timeline